🚚 Free Worldwide Shipping on All Orders!Shop Now
AirCurve 11 ASV with Humidifier and ClimateLineAir Tube
HomeStore

AirCurve 11 ASV with Humidifier and ClimateLineAir Tube

AirCurve 11 ASV with Humidifier and ClimateLineAir Tube

Say hello to next-level sleep!

ResMed's AirCurve 11 ASV adjusts to your individual breathing patterns as they change during the night. The algorithm, called adaptive servo-ventilation (ASV*), detects when you stop breathing and provides a breath.

*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea. 

$1,499.70

Original: $4,999.00

-70%
AirCurve 11 ASV with Humidifier and ClimateLineAir Tube

$4,999.00

$1,499.70

More Images

AirCurve 11 ASV with Humidifier and ClimateLineAir Tube - Image 2
AirCurve 11 ASV with Humidifier and ClimateLineAir Tube - Image 3
AirCurve 11 ASV with Humidifier and ClimateLineAir Tube - Image 4
AirCurve 11 ASV with Humidifier and ClimateLineAir Tube - Image 5
AirCurve 11 ASV with Humidifier and ClimateLineAir Tube - Image 6

AirCurve 11 ASV with Humidifier and ClimateLineAir Tube

Say hello to next-level sleep!

ResMed's AirCurve 11 ASV adjusts to your individual breathing patterns as they change during the night. The algorithm, called adaptive servo-ventilation (ASV*), detects when you stop breathing and provides a breath.

*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea. 

Product Information

Shipping & Returns

Description

Say hello to next-level sleep!

ResMed's AirCurve 11 ASV adjusts to your individual breathing patterns as they change during the night. The algorithm, called adaptive servo-ventilation (ASV*), detects when you stop breathing and provides a breath.

*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.